CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Biogen Idec Inc.(NASDAQ: BIIB) and Elan (NYSE: ELN) today announced it will host a conference call for the Investment Community to discuss the recent events related to TYSABRI® (natalizumab) on Friday, August 1, 2008 at 8:30 a.m. ET/1:30 pm British Summer Time (BST).
